Skip to content

Effect of nebulisation through vibration mesh technique vs jet nebulisation in children with acute asthma

A randomized controlled open label trial (RCT) of vibration mesh technology (Aeroneb) vs conventional jet nebulization in children with moderate to severe Acute Asthma. - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/073107
Enrollment
78
Registered
2024-08-29
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J459- Other and unspecified asthma Health Condition 2: J459- Other and unspecified asthma Health Condition 3: J96-J99- Other diseases of the respiratory system Health Condition 4: J22- Unspecified acute lower respiratory infection

Interventions

Intervention1: Aerogen vibration mesh nebulisation: In children with moderate to severe asthma using aerogen vibration mesh nebulisation technique compare the clinical outcome Intervention2: jet nebul

Sponsors

Nikhita V N
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Any child aged 2- 18 years with moderate to severe acute asthma, i.e. CASS score = 4

Exclusion criteria

Exclusion criteria: 1 Any child with acute asthma who already received nebulization in present episode of exacerbation. 2 cardiovascular disease 3 cystic fibrosis 4 chronic lung disease 5 airway anomalies •immunodeficiency syndromes •coexisting medical conditions such as pneumonia, or if they were in impending respiratory failure. •Patients who already received bronchodilator treatment within 24 hrs of the emergency department presentation.

Design outcomes

Primary

MeasureTime frame
In patients with acute moderate to severe asthma we will assess improvement in CAS Score less than or equal to 2 with clinical improvement(No respiratory distress, improved oral intake, able to comprehend)Timepoint: For first 6 hrs we will assess improvement in CAS score less than or equal to 2 with clinical improvement, followed by assessment every 2-4hrs.

Secondary

MeasureTime frame
• To study the duration of admission rate and hospital stay in both the groups • To study the difference in dosage requirement of SABA after initial first hour nebulization in both groupsTimepoint: 20 months

Countries

India

Contacts

Public ContactBal Mukund

INHS Asvini

bmdoc2002@rediffmail.com8727073888

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026